V
VisEn Medical
VisEn Medical, Inc designs, develops, and commercializes fluorescence in vivo imaging technology platforms The company’s Fluorescence
About VisEn Medical
VisEn Medical, Inc. was a specialized developer of in vivo fluorescence imaging platforms, founded in 2000 by Ralph Weissleder, MD, PhD, and Kirtland Poss. The company's technology originated from research conducted at the Center for Molecular Imaging Research at Massachusetts General Hospital. Dr. Weissleder, a clinician-scientist and professor at Harvard Medical School, brought extensive expertise in molecular imaging, nanotechnology, and systems biology to the venture. His research has consistently focused on developing novel technologies for early disease detection, particularly in cancer and inflammation, which formed the scientific bedrock of VisEn.
The company's core business centered on providing advanced tools for preclinical research. Its product line included Fluorescence Molecular Tomographic (FMT™) imaging systems and a portfolio of proprietary fluorescence imaging agents. These systems enabled researchers to quantitatively visualize and measure a range of biological processes and disease biomarkers deep within living organisms, a significant step in understanding disease progression and the efficacy of potential therapies. The technology was designed to bridge the gap between in vitro cellular studies and in vivo biological activity, offering a clearer path toward understanding human responses to new drugs.
VisEn served a distinct client base that included academic research institutions, pharmaceutical companies, and contract research organizations (CROs). The company generated revenue through the sale of its imaging systems and reagents, such as ProSense®, IntegriSense™, and OsteoSense®. It also collaborated with pharmaceutical partners to create custom molecular imaging agents for specific research needs. In August 2010, PerkinElmer, Inc. acquired VisEn Medical to expand its own cellular imaging business and capabilities in the preclinical research market. The acquisition integrated VisEn's in vivo imaging technologies into PerkinElmer's broader suite of tools for the life sciences and drug discovery pipeline.
Source: Dealroom company dataNews
Open roles
VisEn Medical in the Redwood City ecosystem
The VisEn Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Flagship Pioneering
N47
Spinnaker Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about VisEn Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VisEn Medical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
